Printer Friendly

LEDERLE ANNOUNCES PROSTEP NOW FULLY AVAILABLE; NATIONAL ADVERTISING BEGINS ON THE OLYMPICS THIS WEEK

 LEDERLE ANNOUNCES PROSTEP NOW FULLY AVAILABLE;
 NATIONAL ADVERTISING BEGINS ON THE OLYMPICS THIS WEEK
 WAYNE, N.J., Aug. 5 /PRNewswire/ -- Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), today announced an end to the sporadic supply shortages of its ProStep(TM) nicotine transdermal system and the beginning of a major national advertising campaign for the product, including several TV spots during Olympics coverage this week. Lederle has shipped all open orders for the ProStep 22 mg/day strength, and has begun to distribute the 11 mg/day product strength.
 The 22 mg/day ProStep nicotine patch, widely prescribed as an aid to a comprehensive smoking cessation program, is once again readily available to patients with a physician's prescription, along with the unique ProStep Support Services. The 11 mg/day ProStep product strength, suitable for individuals weighing 100 lbs. or less, is also available. Very substantial consumer demand caused sporadic shortages of ProStep during the months following its January 28 approval.
 Consumer print and television advertising for ProStep are resuming now that sufficient supplies of the product are on pharmacy shelves. To avoid creating disappointment among would-be quitters, Lederle had suspended promotional efforts during the period of brief, sporadic supply shortages. Television commercials for ProStep will begin airing again this week during network coverage of the Olympics, and print advertisements will begin appearing the week of August 10 in such publications as Time, Newsweek and People.
 "Although we never experienced widespread nationwide shortages of ProStep, tremendous consumer demand made it a challenge to supply the product on a continuous basis," said Edward V. Fritzky, vice president of Lederle. "We are now able to meet the demand ProStep has generated, and to help the millions of adult American smokers who truly want to kick their habit."
 "Our medically responsible consumer advertising campaign has achieved an enormous public health benefit," said David H. Mason, M.D., vice president of scientific affairs and medical director of Lederle. "Creating consumer awareness of ProStep has newly motivated hundreds of thousands of smokers to quit. Our campaign is designed to encourage smokers to see their physician and determine whether ProStep is appropriate to help them improve their health and quality of life."
 Increased ProStep availability can be attributed to a production expansion by Elan Corporation, plc., manufacturer of ProStep. Elan installed a second manufacturing unit in their Athlone, Ireland facility to meet high consumer demand for ProStep, which Lederle markets in the U.S.
 In clinical trials using 22 mg/day for six to eight weeks, quit rates with ProStep were significantly higher than those seen with placebo, when both were used with counseling.
 Patients who are prescribed ProStep may enroll free of charge in The ProStep Patient Support Services, the only nicotine patch support services that provide:
 -- The ProStep Support Hotline: live, one-on-one advice, motivation and encouragement by trained smoking cessation specialists via a convenient toll-free support hotline (to date, nearly 8,000 calls have been made to this service);
 -- pharmacists with the educational materials and techniques to advise, encourage and motivate patients on ProStep to stick to their smoking cessation effort. Nearly 6,500 pharmacies are participating in this ProStep Pharmacists Educating Patients Program (P.E.P.P);
 -- The ProStep Commitment: a substantial rebate program for patients who successfully quit smoking on ProStep, later relapsed, and wish to make another attempt to quit;
 -- The ProStep Referral Service: referrals to local smoking cessation programs via a separate toll-free number.
 Lederle Laboratories is a research-intensive organization that manufactures and markets worldwide a broad range of healthcare products, including ethical pharmaceuticals, vaccines, generics, vitamins and nutritionals.
 -0- 8/5/92
 /CONTACT: Pat Fiaschetti of Lederle Labs, 201-831-4684/
 (ACY) CO: Lederle Laboratories ST: New Jersey IN: MTC SU: PDT


LD-KD -- NYW005 -- 6982 08/05/92 10:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 5, 1992
Words:631
Previous Article:ACQUISITION OF HOUSTON OIL & ENERGY, INC. BECOMES EFFECTIVE; GOLDEN TRIANGLE GROWTH CONTINUES
Next Article:GMAC ANNOUNCES INCREASE IN SECOND-QUARTER CONSOLIDATED NET INCOME
Topics:


Related Articles
PROSTEP NICOTINE TRANSDERMAL SYSTEM RECEIVES APPROVAL
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE; MORE THAN FOUR MILLION SHIPPED THUS FAR
ELAN ADDS $200 MILLION OF NICOTINE PATCH PRODUCTION CAPACITY WITH SECOND UNIT; U.S. MARKET SHARE NOW AT 30 PERCENT
LEDERLE LABORATORIES ISSUES A STATEMENT ON PROSTEP
TOWN LEADERS CALL ON PARENTS IN HEARTLAND COMMUNITY TO MAKE NEW YEAR'S RESOLUTION TO QUIT SMOKING FOR CHILDREN'S SAKE
SMOKERS RESPOND POSITIVELY TO PROSTEP(R) NICOTINE PATCH DONATION; ASTHO ENCOURAGES INTERESTED SMOKERS TO LISTEN TO LOCAL MEDIA FOR DETAILS
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
LEDERLE STANDARD PRODUCTS ANNOUNCES AVAILABILITY OF ALPRAZOLAM TABLETS, ONE OF THE FIRST GENERIC VESIONS OF TOP-SELLING ANTI-ANXIETY DRUG

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters